Access the full text.
Sign up today, get DeepDyve free for 14 days.
L. Silverman, S. Sallan (2002)
Treatment of Childhood Acute Lymphoblastic Leukemia
M. Stroun, Jacqueline Lyautey, C. Lederrey, Hugh Mulcahy, Philippe Anker (2001)
Alu Repeat Sequences Are Present in Increased Proportions Compared to a Unique Gene in Plasma/Serum DNAAnnals of the New York Academy of Sciences, 945
G. Cario, M. Stanulla, B. Fine, O. Teuffel, N. Neuhoff, A. Schrauder, T. Flohr, B. Schäfer, C. Bartram, K. Welte, B. Schlegelberger, M. Schrappe (2005)
Distinct gene expression profiles determine molecular treatment response in childhood acute lymphoblastic leukemia.Blood, 105 2
Philippe Anker, François Lefort, V. Vasioukhin, Jacqueline Lyautey, C. Lederrey, X. Chen, M. Stroun, H. Mulcahy, M. Farthing (1997)
K-ras mutations are found in DNA extracted from the plasma of patients with colorectal cancer.Gastroenterology, 112 4
V. Velden, G. Cazzaniga, A. Schrauder, J. Hancock, P. Bader, E. Panzer-Grümayer, T. Flohr, R. Sutton, H. Cavé, H. Madsen, J. Cayuela, J. Trka, C. Eckert, L. Foroni, U. Stadt, K. Beldjord, T. Raff, C. Schoot, J. Dongen (2007)
Analysis of minimal residual disease by Ig/TCR gene rearrangements: guidelines for interpretation of real-time quantitative PCR dataLeukemia, 21
M. Stroun, P. Maurice, Valery Vasioukhin, Jacqueline Lyautey, C. Lederrey, François Lefort, A. Rossier, X. Chen, P. Anker (2000)
The Origin and Mechanism of Circulating DNAAnnals of the New York Academy of Sciences, 906
E. Coustan-Smith, J. Sancho, M. Hancock, B. Razzouk, R. Ribeiro, G. Rivera, J. Rubnitz, J. Sandlund, C. Pui, D. Campana (2002)
Use of peripheral blood instead of bone marrow to monitor residual disease in children with acute lymphoblastic leukemia.Blood, 100 7
Gilbert Fournié, Jean-Paul Courtin, Françoise Laval, Jean-Jacques Chalé, Jacques Pourrat, M. Pujazon, Dominique Lauque, Pierre Carles (1995)
Plasma DNA as a marker of cancerous cell death. Investigations in patients suffering from lung cancer and in nude mice bearing human tumours.Cancer letters, 91 2
M. Stroun, Philippe Anker, P. Maurice, Jacqueline Lyautey, C. Lederrey, M. Beljanski (1989)
Neoplastic characteristics of the DNA found in the plasma of cancer patients.Oncology, 46 5
S. Jahr, H. Hentze, S. Englisch, Dieter Hardt, F. Fackelmayer, R. Hesch, R. Knippers (2001)
DNA fragments in the blood plasma of cancer patients: quantitations and evidence for their origin from apoptotic and necrotic cells.Cancer research, 61 4
M. Esteller, M. Sanchez-Cespedes, R. Rosell, D. Sidransky, S. Baylin, J. Herman (1999)
Detection of aberrant promoter hypermethylation of tumor suppressor genes in serum DNA from non-small cell lung cancer patients.Cancer research, 59 1
M. Stroun, Philippe Anker, Jacqueline Lyautey, C. Lederrey, P. Maurice (1987)
Isolation and characterization of DNA from the plasma of cancer patients.European journal of cancer & clinical oncology, 23 6
P. Anker, M. Stroun (2001)
Tumor-related alterations in circulating DNA, potential for diagnosis, prognosis and detection of minimal residual diseaseLeukemia, 15
H Cave, J Werff ten Bosch, S Suciu, C Guidal, C Waterkeyn, J Otten, M Bakkus, K Thielemans, B Grandchamp, E Vilmer (1998)
Clinical significance of minimal residual disease in childhood acute lymphoblastic leukemia. European Organization for Research and Treatment of Cancer—Childhood Leukemia Cooperative GroupN Engl J Med, 339
T. Flohr, A. Schrauder, G. Cazzaniga, R. Panzer-Grümayer, V. Velden, S. Fischer, M. Stanulla, G. Basso, F. Niggli, B. Schäfer, R. Sutton, R. Koehler, M. Zimmermann, M. Valsecchi, H. Gadner, G. Masera, M. Schrappe, J. Dongen, A. Biondi, C. Bartram (2008)
Minimal residual disease-directed risk stratification using real-time quantitative PCR analysis of immunoglobulin and T-cell receptor gene rearrangements in the international multicenter trial AIEOP-BFM ALL 2000 for childhood acute lymphoblastic leukemiaLeukemia, 22
Anna Rogers, Y. Joe, T. Manshouri, Amanda Dey, I. Jilani, F. Giles, E. Estey, E. Freireich, M. Keating, H. Kantarjian, M. Albitar (2004)
Relative increase in leukemia-specific DNA in peripheral blood plasma from patients with acute myeloid leukemia and myelodysplasia.Blood, 103 7
M. Nakao, J. Janssen, T. Flohr, C. Bartram (2000)
Rapid and reliable quantification of minimal residual disease in acute lymphoblastic leukemia using rearranged immunoglobulin and T-cell receptor loci by LightCycler technology.Cancer research, 60 12
V. Velden, A. Hochhaus, G. Cazzaniga, T. Szczepański, J. Gabert, J. Dongen (2003)
Detection of minimal residual disease in hematologic malignancies by real-time quantitative PCR: principles, approaches, and laboratory aspectsLeukemia, 17
X. Chen, M. Stroun, J. Magnenat, L. Nicod, A. Kurt, Jacqueline Lyautey, C. Lederrey, P. Anker (1996)
Microsatellite alterations in plasma DNA of small cell lung cancer patientsNature Medicine, 2
P. Anker, M. Stroun, P. Maurice (1975)
Spontaneous release of DNA by human blood lymphocytes as shown in an in vitro system.Cancer research, 35 9
V. Vasioukhin, Philippe Anker, P. Maurice, Jacqueline Lyautey, C. Lederrey, M. Stroun (1994)
Point mutations of the N‐ras gene in the blood plasma DNA of patients with myelodysplastic syndrome or acute myelogenous leukaemiaBritish Journal of Haematology, 86
N. Frickhofen, E. Muller, M. Sandherr, T. Binder, M. Bangerter, C. Wiest, M. Enz, Hermann Heimpel (1997)
Rearranged Ig heavy chain DNA is detectable in cell-free blood samples of patients with B-cell neoplasia.Blood, 90 12
Javier Silva, G. Domínguez, M. Villanueva, R. Gonzalez, J. García, C. Corbacho, M. Provencio, P. España, F. Bonilla (1999)
Aberrant DNA methylation of the p16INK4a gene in plasma DNA of breast cancer patientsBritish Journal of Cancer, 80
I. Wong, Y. Lo, Jun Zhang, C. Liew, M. Ng, N. Wong, P. Lai, W. Lau, N. Hjelm, P. Johnson (1999)
Detection of aberrant p16 methylation in the plasma and serum of liver cancer patients.Cancer research, 59 1
Homaira Nawroz, W. Koch, P. Anker, M. Stroun, D. Sidransky (1996)
Microsatellite alterations in serum DNA of head and neck cancer patientsNature Medicine, 2
C. Goessl, R. Heicappell, R. Münker, P. Anker, M. Stroun, H. Krause, M. Müller, K. Miller (1998)
Microsatellite analysis of plasma DNA from patients with clear cell renal carcinoma.Cancer research, 58 20
Jacques Dongen, T. Seriu, E. Panzer-Grümayer, Andrea Biondi, M. Pongers‐Willemse, Lilly Corral, Frank Stolz, M. Schrappe, Giuseppe Masera, W. Kamps, H. Gadner, E. Wering, Wolf-Dieter Ludwig, Giuseppe Basso, Marianne Bruijn, G. Cazzaniga, K. Hettinger, A. Berg, W. Hop, H. Riehm, C. Bartram (1998)
Prognostic value of minimal residual disease in acute lymphoblastic leukaemia in childhoodThe Lancet, 352
Chia-Ni Li, H. Hsu, Tsu‐lan Wu, K. Tsao, Chien‐feng Sun, James Wu (2003)
Cell‐free DNA is released from tumor cells upon cell death: A study of tissue cultures of tumor cell linesJournal of Clinical Laboratory Analysis, 17
Y. Fujiwara, D. Chi, He‐jing Wang, Pond Keleman, D. Morton, R. Turner, D. Hoon (1999)
Plasma DNA microsatellites as tumor-specific markers and indicators of tumor progression in melanoma patients.Cancer research, 59 7
V. Velden, E. Panzer-Grümayer, G. Cazzaniga, T. Flohr, R. Sutton, A. Schrauder, G. Basso, M. Schrappe, J. Wijkhuijs, M. Konrad, C. Bartram, G. Masera, A. Biondi, J. Dongen (2007)
Optimization of PCR-based minimal residual disease diagnostics for childhood acute lymphoblastic leukemia in a multi-center settingLeukemia, 21
D. Jachertz, P. Anker, P. Maurice, M. Stroun (1979)
Information carried by the DNA released by antigen-stimulated lymphocytes.Immunology, 37 4
M Stroun, J Lyautey, C Lederrey, HE Mulcahy, P Anker (2001)
Alu repeat sequences are present in increased proportions compared to a unique gene in plasma/serum DNA: evidence for a preferential release from viable cells?Ann N Y Acad Sci, 945
J. Dongen, T. Seriu, E. Grumayer, A. Biondi, Willemse Pongers, L. Corral, F. Stolz, M. Schrappe, G. Masera, W. Kamps, H. Gadner, M. Willemse, W. Ludwig, G. Basso, De Mac, G. Cazzaniga, K. Hettinger, A. Berger, W. Hop, C. Bartram (1998)
PROGNOSTIC VALUE OF MINIMAL RESIDUAL DISEASE IN CHILDHOOD ACUTE LYMPHOBLASTIC LEUKEMIA. A PROSPECTIVE STUDY OF THE INTERNATIONL BFM STUDY GROUP., 352
V. Velden, D. Jacobs, A. Wijkhuijs, W. Comans-Bitter, M. Willemse, K. Hählen, W. Kamps, E. Wering, J. Dongen (2002)
Minimal residual disease levels in bone marrow and peripheral blood are comparable in children with T cell acute lymphoblastic leukemia (ALL), but not in precursor-B-ALLLeukemia, 16
S. Leon, B. Shapiro, D. Sklaroff, M. Yaros (1977)
Free DNA in the serum of cancer patients and the effect of therapy.Cancer research, 37 3
H. Cavé, J. Bosch, S. Suciu, C. Guidal, C. Waterkeyn, J. Otten, M. Bakkus, K. Thielemans, B. Grandchamp, E. Vilmer, B. Nelken, M. Fournier, P. Boutard, E. Lebrun, F. Mechinaud, R. Garand, A. Robert, N. Dastugue, E. Plouvier, E. Racadot, A. Ferster, J. Gyselinck, O. Fenneteau, M. Duval, G. Solbu, A. Manel (1998)
Clinical Significance of Minimal Residual Disease in Childhood Acute Lymphoblastic LeukemiaThe New England Journal of Medicine, 339
B. Shapiro, Milankumar Chakrabarty, E. Cohn, S. Leon (1983)
Determination of circulating DNA levels in patients with benign or malignant gastrointestinal diseaseCancer, 51
Tzong-Hae Lee, Leilani Montalvo, Vera Chrebtow, M. Busch (2001)
Quantitation of genomic DNA in plasma and serum samples: higher concentrations of genomic DNA found in serum than in plasmaTransfusion, 41
The analysis of total plasma DNA and the monitoring of leukemic clone-specific immunoglobulin and/or T-cell receptor gene rearrangements for the evaluation of minimal residual disease (MRD) in the plasma may be useful tools for prognostic purposes or for early detection of subclinical disease recurrence in children with acute lymphoblastic leukemia (ALL). The aim of this paper is to establish reference ranges for total plasma DNA concentrations and to test the feasibility of MRD measurements employing plasma DNA from children with ALL by using real-time quantitative (RQ)-PCR. Despite wide inter-individual variation, the median concentrations of total plasma DNA for 12 healthy donors (57 ng/ml), 21 children with ALL after day 4 of treatment initiation (62 ng/ml) and 13 children with other malignancies (76 ng/ml) were similar. However, ALL patients had significantly higher concentrations at diagnosis (277 ng/ml) and on treatment day 3 (248 ng/ml) before returning to normal afterwards. Early plasma DNA MRD kinetics could be established for 15 ALL patients and showed good concordance with bone marrow MRD. Plasma DNA was higher in children with ALL at diagnosis but returned to normal within the first four treatment days. Despite low concentrations of DNA, it is feasible to measure MRD kinetics in plasma DNA during ALL induction therapy by adapted real-time PCR methodologies.
Annals of Hematology – Springer Journals
Published: Sep 1, 2009
Read and print from thousands of top scholarly journals.
Already have an account? Log in
Bookmark this article. You can see your Bookmarks on your DeepDyve Library.
To save an article, log in first, or sign up for a DeepDyve account if you don’t already have one.
Copy and paste the desired citation format or use the link below to download a file formatted for EndNote
Access the full text.
Sign up today, get DeepDyve free for 14 days.
All DeepDyve websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.